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ABSTRACT
DNA-binding and RNA-binding proteins are usually
considered ‘undruggable’ partly due to the lack of
an efficient method to identify inhibitors from existing small molecule repositories. Here we report a
rapid and sensitive high-throughput screening approach to identify compounds targeting protein–
nucleic acids interactions based on protein–DNA or
protein–RNA interaction enzyme-linked immunosorbent assays (PDI-ELISA or PRI-ELISA). We validated
the PDI-ELISA method using the mammalian highmobility-group protein AT-hook 2 (HMGA2) as the
protein of interest and netropsin as the inhibitor of
HMGA2–DNA interactions. With this method we successfully identified several inhibitors and an activator for HMGA2–DNA interactions from a collection of
29 DNA-binding compounds. Guided by this screening excise, we showed that netropsin, the specific inhibitor of HMGA2–DNA interactions, strongly inhibited the differentiation of the mouse pre-adipocyte
3T3-L1 cells into adipocytes, most likely through a
mechanism by which the inhibition is through preventing the binding of HMGA2 to the target DNA sequences. This method should be broadly applicable
to identify compounds or proteins modulating many
DNA-binding or RNA-binding proteins.

tiate DNA replication (1–3). Transcription factors, on the
other hand, orchestrate specific gene expression patterns in
response to developmental and/or environmental stimuli
(4–6). Abnormal expression and/or aberrant regulation of
certain transcription factors are involved in human oncogenesis (7), and tumor proliferation and malignancy (8,9). In
fact, transcription factors are considered as important therapeutic targets due to their crucial roles in many diseases
including cancers (7). However, since transcription factors
usually do not have enzymatic activities suitable for chemical intervention, they are considered ‘undruggable’ targets
(10). Nevertheless, it is possible to design chemistry to disrupt protein–DNA and/or protein–protein interactions to
modulate the functionalities of transcription factors, such
as c-Myc and STAT3 (signal transducer and activator of
transcription 3). Indeed, several high-throughput screening methods have been used to identify inhibitors targeting protein–protein interactions (7,11,12). One challenge
is to develop rapid and efficient high-throughput screening assays to identify inhibitors from the millions of compounds found in small molecule libraries that may target
protein–DNA, protein–RNA and protein–protein interactions. Here we report a rapid and sensitive high-throughput
screening method to survey compound libraries targeting
protein–DNA and protein–RNA interactions, a necessary
step toward converting these ‘undruggable’ targets ‘druggable’.
MATERIALS AND METHODS
Materials

INTRODUCTION
Protein–DNA interactions play critical roles in many essential biological events, such as DNA replication, recombination and transcription. For instance, the first step of
DNA replication is the binding of the origin-binding proteins, such as DnaA for bacteria and origin recognition
complex for eukaryotes, to DNA replication origins to ini* To

Biotin-labeled hairpin DNA oligomer FL814 containing a
specific binding site of HMGA2 was purchased from Eurofins MWG Operon, Inc. Streptavidin covalently coated
96-well plates (NUNC Immobilizer Streptavidin-F96 clear)
were from Thermo Fisher Scientific, Inc. Antibody against
HMGA2 (HMGA2 (D1A7) Rabbit mAb) and Anti-rabbit
IgG, HRP-linked Antibody #7074 were purchased from
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Cell Signaling, Inc. Ultra TMB-ELISA was bought from
Thermo Fisher Scientific, Inc. The mammalian high mobility group protein AT hook 2 (HMGA2) was purified as
described previously (13). Netropsin, insulin and Oil red O
were purchased from Sigma and used without further purification. The following extinction coefficients were used
to determine the concentration of different compounds:
netropsin, 21 500 M−1 cm−1 at 296 nm, meso-tetra (Nmethyl-4-pyridyl) porphine tetratosylate (TMPyP4), 226
000 M−1 cm−1 at 424 nm and HMGA2, 5810 M−1 cm−1 at
280 nm. A compound library consisting of 29 DNA-binding
compounds was a generous gift of Prof. Jonathan B. Chaires
(University of Louisville, KY, USA). Dulbecco’s modified
Essential Medium (DMEM) and fetal bovine serum (FBS)
were purchased from Invitrogen, Inc.
Protein–DNA interaction ELISA assays to screen compounds targeting HMGA2–DNA interactions
In this method, the first step is to bind a biotin-labeled
oligomer to a streptavidin-coated 96-well plate. A synthetic
DNA hairpin oligomer FL814 carrying a specific binding
site of HMGA2, SELEX1, was used. The DNA oligomer
was dissolved into an annealing buffer (10 mM Tris-HCl
pH 8.0, 50 mM NaCl) at 100 M and heated in a water bath
to 95◦ C for 10 min. The denatured DNA oligomer FL814
was cooled down slowly for the formation of the doublestranded DNA. The streptavidin-coated plate was washed
three times with 300 l of 2×SSCT (saline-sodium citrate
buffer with Tween 20: 30 mM trisodium citrate pH 7.0, 200
mM NaCl and 0.05% Tween 20). After the wash, 100 l of
0.1 M FL814 was added to each of the wells. The plate
was then incubated at room temperature on a shaking platform for 1 h. After removing the DNA solution, the plate
was washed three times with 300 l of 2×SSCT. In the next
step, 300 l of 3% bovine serum albumin in 2×SSCT was
added to each of the wells to block the surface overnight
at 4◦ C. The plate was then washed three times with 300 l
of 2×SSCT. The next step was the binding of HMGA2 to
the DNA on the well surface of the 96-well plates. A titration of various concentrations of HMGA2 was carried out
for the determination of the optimal signal-to-noise ratio
for the assay. In this step, the DNA-binding compounds
can be added to the wells to inhibit or enhance HMGA2
binding to the DNA oligomer FL814. After the proteinbinding step, the plate was washed three times with 300 l
of 2×SSCT. One hundred microliter of the first antibody
against HMGA2 (Rabbit mAb) in 2×SSCT was added to
the wells and the plate was then incubated at room temperature for 1 h on a shaking platform. The plate was washed
three times with 300 l of 2×SSCT. One hundred microliter of the second antibody against HMGA2 (HRP-linked
anti-Rabbit IgG) in 2×SSCT was added to the wells and the
plate was then incubated at room temperature for 1 h on a
shaking platform. The plate was washed three times with
300 l of 2×SSCT. After the wash, 100 l of Ultra TMB
ELISA was added to the wells. The plate was then incubated
at room temperature for 15 min on a shaking platform. The
reaction was then stopped with 100 l of 2M H2 SO4 . The
results were quantified with photometric detection using a
microplate reader.
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The protein–DNA interaction enzyme-linked immunosorbent assays (PDI-ELISA) were also used to
determine the apparent DNA dissociation constant (Kd )
by nonlinear-least-squares fitting the following equation
using the program Origin:

(a + x + Kd ) − (a + x + Kd )2 − 4ax
R=
,
2a
where R, a and x represent the DNA-binding ratio, the total DNA concentration and the total protein concentration,
respectively. The apparent inhibitory IC50 values were obtained using the following equation (14):
%HMGA2 binding to DNA =
100/[1 + C ∗ (1 + K c2 ∗ C)/[IC50 (1 + Kc2 ∗ IC50 )]],
where Kc2 is a macroscopic binding constant for inhibitor
binding to DNA, IC50 is the concentration of inhibitor that
causes 50% inhibition of HMGA2 binding to DNA and C
is the concentration of an inhibitor.
Z-factor of the PDI-ELISA was determined using a full
96-well plate in which 48 wells are for positive controls in
the presence of 1 M of HMGA2 and the rest 48 wells for
negative controls in the absence of HMGA2. Z-factor was
calculated by the following formula:
Z=1−

3(σp + σn )
,
|μp − μn |

where  p ,  n , p and n represent the sample means and
standard deviations for positive (p) and negative (n) controls, respectively.
Competition dialysis assays
The competition dialysis assays were carried out according
to previously published procedures (15). Briefly, a volume
of 0.3 ml of FL814 (3 M) or the HMGA2-FL814 complex
(3 M) was pipeted into a separate 0.3 ml disposable dialyzer. The dialysis units were then placed into a beaker with
200 ml of 2×SSCT containing 0.73 M of TMPyP4. The
dialysis was allowed to equilibrate with continuous stirring
of 72 h at room temperature (24◦ C). After the dialysis, the
free, bound and total concentrations of TMPyP4 were determined spectrophotometrically.
Pre-adipocytes and differentiation
Mouse pre-adipocytes (3T3-L1 cells) were a gracious gift
from Dr Jun Liu at Mayo Clinic. 3T3-L1 cells were maintained in DMEM supplemented with 10% FBS, 100 U/ml
penicillin, 100 g/ml streptomycin and 5 g/ml plasmocin.
The cells were grown under normal culture conditions of 5%
CO2 and humidity. Cells were maintained for a minimum
of three passages in linear growth prior to differentiation.
To differentiate the 3T3-L1 pre-adipocytes into adipocytes,
we used the protocol previously described by Zebisch et al.
(16). Briefly, 3T3-L1 pre-adipocytes were sub-cultured in
DMEM supplemented with 5% newborn calf serum, 100
U/ml penicillin, 100 g/ml streptomycin and 5 g/ml plasmocin (Basal Media 1 – BM1). The cells were then plated at
6×105 cells per dish in 35-mm dishes, 3×105 cells per well in
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a 12-well plate, 1.5×105 cells in a 24-well plate or 3.0×104
cells per well in a 96-well plate. The cells were grown to confluency with BM1 replacement every other day. Following
48 h of confluency, 3T3-L1 cells were treated with Differentiation medium 1 (DM1), which is BM1 supplemented
with 0.5 M iso-butyl-methylxanthine, 0.25 M dexamethasone, 1 g/ml insulin and 2 g/ml rosiglitazone. After
48 h, the medium was replaced with differentiation medium
2 (DM2); this is BM1 supplemented with 1 g/ml insulin.
On the seventh day, the cells were placed in DMEM with
FBS. The cells were cultured to the date indicated in the experiments below with media changes every other day. The
presence of adipogenesis was confirmed by microscopic detection of adipose bodies in the cells. For our experiments,
only cultures with >80% differentiation were used.
Western blot analysis
To isolate proteins from cells for western blot analysis, cells
were plated as indicated above, and following differentiation and drug treatment, cells were lysed and proteins
were harvested as previously described (17). Briefly, cells
were washed twice in phosphate buffered saline (PBS) and
lysed in radioimmunoprecipitation assay buffer (50 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5%
deoxycholate, 0.1% SDS) supplemented with protease inhibitors (1 mM PMSF and Halt Protease Inhibitor Cocktail (Thermo)) and Halt phosphatase inhibitors (Thermo).
Cells were then incubated at 4◦ C for 5 min with gentle rocking. Cells were scraped from the well and transferred to a
sterile micro-centrifuge tube. Following a 10-min incubation on ice, the cells disruption was finished using sonication. The lysate was centrifuged at 14 000×g for 15 min to
remove debris. Protein concentrations of the supernatant
were determined using the Pierce BCA Assay kit protocol. Proteins were resolved by sodium dodecyl sulphatepolyacrylamide gel electrophoresis and transferred onto
polyvinylidene difluoride membranes. Membranes were incubated with Li-Cor Biosciences Odyssey Blocking for at
least 1 h at room temperature or overnight at 4◦ C. The
membranes were incubated with primary antibodies specific for FABP4, HMGA2 and Actin (Cell Signaling Technology 3544, 5269 and 3700, respectively) at dilutions of
1:1000 in blocking buffer. Membranes were washed three
times for 5 min in 1× TBST (20 mM Tris-HCl, pH 6.7, 137
mM NaCl, 0.1% Tween 20). Membranes were incubated
with secondary antibodies in blocking buffer at 1:20 000 for
fluorescently conjugated antibodies purchased from Li-Cor
Biosciences. Membranes were again washed three times for
5 min in 1×TBST. Western blots were developed using fluorescence detection using the LI-COR Odyssey CLx near
infrared scanner.
Oil Red O staining
Following differentiation and drug treatment, Oil Red O
staining was used to qualitatively and quantitatively assess
the level of neutral lipids in the differentiated cells. For qualitative assessment by phase microscopy, cells were washed
twice in PBS and then fixed with 10% formalin for 30 min
at room temperature. Oil Red O was reconstituted at 300
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mg per 100 ml of isopropanol. The Oil Red O solution was
prepared for staining by adding 20 ml of deionized water to
30 ml of the Oil Red O stock solution and filtered. The cells
were then incubated for 5 min in 60% isopropanol. The Oil
Red O working solution was then added to cells for 5 min.
The monolyers were then rinsed clean with deionized water. The cells were then visualized using phase microscopy
on the EVOS XL Core microscope. For quantitative assessment of adipogenesis in 96-well formats, cells were lysed in
dimethylsulfoxide (DMSO) following the water wash of Oil
Red O stained cells. The DMSO released the intracellular
Oil Red O into the solution. The absorbance (492 nm) was
measured using the BioTek Synergy H1 plate reader.
In-cell western analysis
Specific protein levels were analyzed using in-cell western
technology (18). During differentiation and drug administration, 3T3-L1 cells were fixed in 4% paraformaldehyde in
PBS for 25 min at room temperature. Pre-adipocytes were
quenched by washing the cells in 100 mM glycine for 5 min
at room temperature. The cells were permeabilized by incubating the cells in 0.2% Triton X-100 in PBS for 30 min
at room temperature. The cells were then blocked using LICOR Odyssey Blocking Buffer (LI-COR Biosciences, 927–
40100) for 1 h at room temperature. Cells were then incubated with a primary antibody for HMGA2 (Cell Signaling
Technologies #5269) at a 1:500 dilution in LI-COR Odyssey
Blocking Buffer supplemented with 0.1% Tween-20 for 2.5 h
at room temperature. The cells were washed in 0.1% Tween
in PBS. Secondary antibodies (IRDye 800CW anti-rabbit,
LI-COR Biosciences, 926–32211) were incubated at a dilution of 1:1000 in LI-COR Blocking Buffer supplemented
with 0.1% Tween-20 for 1 h. Concurrent to the addition of
secondary antibody TO-PRO-3 (Invitrogen) was added at
a 1:1000 dilution as a normalization control for cell number and incubated for 1 h. The cells were washed again in
0.1% Tween-20 in PBS. Plates were then scanned on the LICOR Biosciences Odyssey CLx Infrared Imaging System
and quantified using the LI-COR in-cell western analysis
in Image Studio.
Statistical analysis
A minimum of eight technical replicates was considered for
all cell-based studies performed in 96-well formats, while
technical replicates were performed for western blot analysis and microscopy; additionally, a minimum of four biological replicates were evaluated for our studies. To determine
statistical significance, Student’s paired t test was employed
for significance between treatments. Statistical significance
is indicated by an asterisk in figures in which the P value is
<0.05. Data are displayed as means with error bars representing plus and minus one standard deviation.
RESULTS AND DISCUSSION
Figure 1 illustrates the concept of the high-throughput
screening assay in which the PDI-ELISA (19–21) is used.
The first step is to bind a biotin-labeled oligomer to the
streptavidin-coated multiple-well plates. Either a synthetic
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Figure 2. Inhibition of HMGA2 binding to FL814 by netropsin. (A) The
titration experiment of HMGA2 to the DNA substrate FL814 in 2×SSCT.
The apparent DNA dissociation constant was determined to be 0.86±0.12
M according to the method described in Materials and Methods. The
standard deviation was calculated according to three different titration experiments. (B) The netropsin titration experiments were used to determine
the apparent inhibitory IC50 (9.30±0.78 nM). The standard deviation was
calculated according to three different titration experiments.

Figure 1. The concept of a high-throughput screening method to identify
compounds or proteins targeting protein–nucleic acids interactions. The
first step is to link a biotin-labeled oligomer to surface of a multiple-well
plate through biotin–streptavidin interaction. After the surface-blocking
step, a nucleic acids–binding protein is added to the wells to bind to the
oligomer. The compounds or proteins of interest can also be added to
the wells to inhibit or enhance the protein binding, which is the basis of
the method for high-throughput drug screening. Colorimetric, chemiluminescence or fluorescence methods can be used to detect whether the compounds or proteins inhibit or enhance the binding capacities of the nucleic
acids–binding protein.

hairpin or double-stranded DNA oligomer containing a
binding sequence for a sequence-specific DNA-binding protein, such as transcription factors, may be used. After blocking the well surface by a blocking agent, the DNA-binding
protein is added to the wells to bind to the DNA oligomer.
The DNA-binding compounds are also added to the wells
to inhibit or enhance the protein binding to the DNA, which
is the basis of the method for high-throughput drug screening. Colorimetric, chemiluminescence or fluorescence detection can be used to determine the extent by which compounds inhibit or enhance the DNA-binding capacities of
the DNA-binding protein. The apparent inhibitory or stimulatory IC50 of the DNA-binding drug can be determined
as well.
We validated the concept using the mammalian highmobility-group protein AT-hook 2 (HMGA2) as the
sequence-specific DNA-binding protein. HMGA2 is a
multi-function nuclear transcription factor directly linked
to oncogenesis (22,23) and obesity (24,25). It was also involved in human height (26,27), stem cell youth (28) and hu-

man intelligence (29). These functionalities make HMGA2
one of the most intriguing proteins studied so far and a
valuable candidate drug target (14,30). HMGA2 is a small
DNA-binding protein carrying three ‘AT hook’ DNAbinding motifs that specifically recognize the minor groove
of AT-rich DNA sequences (31). We used a biotin-labeled
oligomer (a hairpin) FL814 containing a specific binding
site of HMGA2, SELEX 1 (14) (Supplementary Figure
S1) and colorimetric detection assays for our experiments.
Under the experimental conditions used in this study, the
dissociation constant of HMGA2 with FL814 was estimated to be 0.86±0.12 M (Figure 2A), which is consistent with our previous published results (31). Netropsin, a
well-characterized AT minor groove binder and a potent inhibitor of HMGA2–DNA interactions (14), was used as a
model inhibitor for the proof-of-concept experiment. Results in Figure 2B clearly demonstrate that netropsin is indeed a strong inhibitor of HMGA2–DNA interactions with
an IC50 of 9.30±0.78 nM. Z factors for three consecutive
days were determined to be 0.66, 0.68 and 0.77 using our
described assay conditions (Materials and Methods) with
manual pipetting. The Z-factor may be higher if automation were used.
Using the validated screening assay, we screened a collection of 29 different DNA-binding compounds targeting HMGA2–DNA interactions. These potential inhibitors
include eight DNA intercalators, six DNA minor groove
binders, six DNA triplex binders, six DNA quadruplex
binders and three miscellaneous DNA binders. Figure 3 and
Supplementary Table S1 show our results. At 100 nM of
the compound added to the assays, it is apparent that three
DNA minor groove binders (netropsin, DAPI and Hoechst
33258) and two bisintercalators (WP631 and WP762) are
able to potently inhibit HMGA2 binding to the target sequence. The IC50 values confirmed these results (Supplementary Table S2). We would like to point out that although
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Figure 3. The inhibition of HMGA2-FL814 interactions by different DNA-binding compounds at 100 nM in 2×SSCT. Nt, Hst, EB and Dox represent
netropsin, Hoechst 33258, ethidium bromide and doxorubicin, respectively. Netropsin, WP631, DAPI and Hoechst 33258 were able to completely inhibit
the HMGA2-FL814 interactions under our experimental conditions.

some of these compounds have strong absorbance around
420 nm, their contribution to the final absorbance is negligent because the solution containing these colorful compounds was removed and the wells were washed several
times before measuring OD420 values.
Surprisingly and intriguingly, we found that meso-tetra
(N-methyl-4-pyridyl) porphine tetratosylate (TMPyP4) is
able to dramatically enhance the binding of HMGA2 to
the target DNA sequence (FL814) (Supplementary Figure
S2). To demonstrate the enhancement, we used a dilution
of 1:2500 for the second antibody, HRP-linked anti-rabbit
IgG. We also shortened the incubation time of the final
step from 15 min to 5 min. In this way, the OD450 value
of HMGA2 addition alone was sufficiently low. Adding
TMPyP4 to the wells dramatically increased the absorbance
at 450 nm (Figure 4). In contrast, meso-tetra (N-methyl2-pyridyl) porphine tetrachloride (TMPyP2), a structurally
similar compound, was not able to stimulate the binding of
HMGA2 to FL814 (Figure 4). In the presence of TMPyP4,
the dissociation constant of HMGA2 to FL814 (Kd ) was determined to be 0.19±0.02 M (Supplementary Figure S3),
∼4-fold enhancement of the binding of HMGA2 to FL814.
Since FL814 is a hairpin, it is possible that TMPyP4 binds
to the loop region of the oligomer to enhance the binding
affinity of HMGA2 to FL814. Nevertheless, using a doublestranded DNA oligomer carrying the SELEX1 sequence
without the loop region, TMPyP4 was also able to enhance
the binding (Supplementary Figure S4), suggesting that the
binding of TMPyP4 to the loop region is not the mechanism of the enhancement. In this study, we also carried
out a competition dialysis assay (15) in which a volume of
0.3 ml of FL814 (3 M) or the HMGA2-FL814 complex
(3 M) was pipeted into a separate 0.3 ml disposable dialyzer and dialyzed against 200 ml of 0.73 M of TMPyP4 in
2×SSCT buffer extensively. Results in Supplementary Figure S5 show that TMPyP4 was able to bind to both FL814

Figure 4. The enhancement of HMGA2 binding to FL814 by TMPyP4.
The titration experiments using different concentrations of TMPyP4 (circles) and TMPyP2 (squares) were performed as described in Materials and
Methods. One hundred nanomolar of FL814 and 1 M of HMGA2 were
used in these experiments.

and the FL814-HMGA2 complex tightly, and HMGA2 did
not block the binding of TMPyP4 to FL814. These results
also showed that two molecules of TMPyP4 bind to one
molecule of FL814.
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Figure 5. Inhibition of HMGA2 by netropsin prevents 3T3-L1 adipogenesis. (A) Western blot analysis was used to confirm the increased expression of HMGA2 during adipogenesis. FABP4 was used as a control for increased gene expression during early adipogenesis, while actin was used as
a loading control. (B) The fluorescent intensity of HMGA2 expression was
quantified using the Image Studio Software (LI-COR Bioscience). The expression level of HMGA2 was measured across four biological replicates.
(C) Adipogenesis was quantitatively measured by Oil Red O staining of
3T3-L1 cells. This method was employed to calculate the IC50 of Netropsin
for this process over a dose curve. An image of this approach is displayed.
(D) The absorbance of Oil Red O was determined using absorbance at 492
nm. C-75, an inhibitor of fatty acid synthase, was used as a control for
inhibition of adipogenesis. (E) Oil Red O staining was also assessed qualitatively in the presence and absence of netropsin using phase microscopy.
(F) The impact of netropsin exposure on HMGA2 expression levels was
assessed using an in-cell western approach. TO-PRO-3 was used to normalize HMGA2 expression levels to cellular DNA content. (G) Normalized HMGA2 expression was assessed in 3T3-L1 cells exposed to DMSO
and netropsin.

Previous studies showed that HMGA2 plays an important role in the differentiation of the mouse NIH 3T3-L1
pre-adipocyte cells into adipocytes (32) (Figure 5A and B).
Knockdown of HMGA2 by miRNA let-7 significantly inhibited 3T3-L1 differentiation (32). Since netropsin is a potent inhibitor of HMGA2 binding to AT-rich DNA sequences (Figure 2B), this compound should be able to
inhibit the differentiation of 3T3-L1 into adipocytes. Indeed, results in Figure 5 clearly demonstrate that netropsin
strongly inhibited the differentiation of 3T3-L1 cells. At
10 M, a concentration much lower than its cytotoxicity
IC50 of 44.7 M and above (33), netropsin was able to inhibit >50% of neutral lipid production measured by Oil
red O staining in the differentiated cells (Figure 5D and
E). The inhibition IC50 of neutral lipids in the differentiated cells was calculated to be 7.9±1.1 and 3.7±0.8 M for
netropsin and C-75 (an inhibitor of fatty acid synthase), respectively. As expected, HMGA2 was also expressed in fully
differentiated 3T3-L1 cells even in the presence of netropsin
(Figure 5F and G). These results strongly suggest that the
inhibition of differentiation of 3T3-L1 to adipocytes was
likely through a mechanism by which netropsin prevents
HMGA2 from binding to its target DNA sequences on the
chromosome. We have to point out here that the direct interactions of netropsin with DNA may also affect other DNA
metabolic pathways and therefore inhibit the differentia-
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Figure 6. Possible schemes to screen inhibitors or activators targeting
protein–DNA interactions by PDI-ELISA. (A) This screening scheme can
be used to identify small molecule inhibitors that upon bind to the DNAbinding proteins cause the protein conformation change and dissociate the
protein from the target DNA sequence. (B) Certain transcription factors
do not bind to the target DNA sequence in the absence of a small molecule
ligand. This screening scheme can be used to identify these small molecule
ligands. (C) Certain small molecules or proteins act as activators to help a
protein binding to a target DNA sequence. This screening scheme can be
used to identify such activators using PDI-ELISA. Please see Figure 1 for
the meaning of different symbols.

tion. Nevertheless, further studies are needed to determine
the inhibition mechanism. Since the over- and/or aberrantexpression of HMGA2 has been directly attributed to the
formation of the malignant tumors (22,30,34,35) and the expression level of HMGA2 often correlates with the degree
of malignancy, the existence of metastasis, and a poor prognosis (36,37), netropsin and similar compounds should have
potent anticancer and anti-metastasis activities by preventing HMGA2 from binding to its target sites on chromosome
(33).
Although we showed here that PDI-ELISA was successfully used to identify small molecule DNA-binding inhibitors that block the binding of HMGA2 to its DNAbinding sites, this method can also be used to screen nonDNA binding ligands that inhibit or activate the binding of
a protein to specific DNA sequences. For instance, as described in Figure 6A, PDI-ELISA can be used to screen
small molecule compounds that prevent certain transcription factors from binding to the target DNA sequences. The
Escherichia coli lac repressor is such a transcription factor
that will dissociate from its binding sites, i.e. lac operators,
upon binding to an inducer, such as IPTG (38). One should
be able to use PDI-ELISA to identify inducers or small
molecule ligands to inhibit the binding of transcription factors similar to the lac repressor to their DNA-binding sites.
Additionally, certain transcription factors, such as eukaryotic nuclear receptors (39), do not tightly bind to the target DNA sequences in the absence of a ligand. PDI-ELISA
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could be a great tool to screen and identify small molecule
ligands that enable the transcription factor binding to the
target DNA sequence (40) (Figure 6B). Furthermore, small
molecule or protein activators may induce DNA conformational change and therefore greatly enhance the DNA
binding of a DNA-binding protein to the target DNA sequence. PDI-ELISA could be used to identify such activators. Indeed, using PDI-ELISA, we found that TMPyP4
significantly enhanced the binding of HMGA2 to the target DNA sequence, i.e. SELEX1 (Figure 4). This screening
method can also be utilized to screen proteins from cellular extracts that inhibit or enhance the targeted protein–
nucleic acids interactions. It should be pointed out that the
same concept could be used to screen compounds targeting RNA–protein interactions as well. It is foreseeable that
this versatile method will be used extensively to identify
compounds or proteins of interest targeting many specific
protein–nucleic acids interactions in the near future.
In summary, we have developed a rapid and sensitive
high-throughput screening method, i.e. PDI-ELISA, for the
identification of inhibitors and activators targeting protein–
DNA interactions. Using this method, we successfully
identified several potent inhibitors including netropsin for
HMGA2–DNA interactions from a collection of 29 different DNA-binding compounds. We also found that TMPyP4
significantly enhances the binding of HMGA2 to the target DNA sequence. Additionally, we demonstrated that
netropsin inhibited the differentiation of the preadipocyte
NIH 3T3-L1 cells to adipocytes, most likely through the inhibition of HMGA2 binding to the target DNA sequences.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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